ストックスクリーナーアプリを入手
0.2973
3.66%
-0.0113
アフターアワーズ：
.30
0.0027
+0.91%
前日終値:
$0.3086
開ける：
$0.3065
24時間の取引高:
2.80M
Relative Volume:
0.30
時価総額：
$53.03M
収益：
-
当期純損益:
$-12.89M
株価収益率:
-0.1175
EPS:
-2.53
ネットキャッシュフロー:
$-11.95M
1週間 パフォーマンス:
-8.33%
1か月 パフォーマンス:
+27.11%
6か月 パフォーマンス:
-39.50%
1年 パフォーマンス:
-15.06%
1日の値動き範囲:
$0.29
$0.3081
1週間の範囲:
$0.2741
$0.3194
52週間の値動き範囲:
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
Compare PSTV vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.2973 | 55.05M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-03 | 開始されました | Lake Street | Buy |
| 2025-09-03 | アップグレード | D. Boral Capital | Hold → Buy |
| 2025-03-17 | 開始されました | D. Boral Capital | Buy |
| 2021-01-25 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-10-16 | 開始されました | Maxim Group | Buy |
Plus Therapeutics Inc (PSTV) 最新ニュース
138,897,548 Common Stock of Plus Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-FEB-2026. - marketscreener.com
Certain Warrants of Plus Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-FEB-2026. - marketscreener.com
Certain Restricted Stock Units of Plus Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-FEB-2026. - marketscreener.com
Lake Street Sticks to Their Buy Rating for Plus Therapeutics (PSTV) - The Globe and Mail
Plus Therapeutics (PSTV) CFO granted RSUs and stock options package - Stock Titan
PLUS Therapeutics (PSTV) CEO receives large RSU and stock option grants - Stock Titan
PLUS THERAPEUTICS, Inc.Common Stock (NQ: PSTV - The Chronicle-Journal
PSTV SEC FilingsPlus Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ - Bitget
Plus Therapeutics, Inc. Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ - marketscreener.com
Plus Therapeutics (PSTV) Gains New CPT Code for Innovation in Br - GuruFocus
Plus Therapeutics announces new Category III CPT code - marketscreener.com
Plus Therapeutics Receives AMA Approval for New CPT Code for REYOBIQ in Treatment of CNS Cancers - Quiver Quantitative
New AMA code tracks REYOBIQ therapy in aggressive brain cancers - Stock Titan
PSTV Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Value Recap: Is Plus Therapeutics Inc stock undervalued right nowWeekly Stock Summary & Short-Term Swing Trade Alerts - baoquankhu1.vn
Aug EndMonth: Is Plus Therapeutics Inc stock undervalued right nowMarket Weekly Review & Comprehensive Market Scan Reports - baoquankhu1.vn
Is Plus Therapeutics Inc. in accumulation or distribution phase2025 Retail Activity & Short-Term Trading Opportunity Alerts - mfd.ru
Plus Therapeutics Updates Executive Compensation, Approves 2025 Bonuses - The Globe and Mail
Aug Gainers: Can Plus Therapeutics Inc stock double in the next yearJuly 2025 Drop Watch & Stock Timing and Entry Methods - baoquankhu1.vn
Is Plus Therapeutics Inc. stock showing strong momentumGlobal Markets & Trade Opportunity Analysis - mfd.ru
Can Plus Therapeutics Inc. stock double in the next year2025 Retail Activity & Daily Market Momentum Tracking - mfd.ru
Aug Decliners: Can Plus Therapeutics Inc stock double in the next yearQuarterly Risk Review & Capital Efficient Trading Techniques - baoquankhu1.vn
Aug EndMonth: What is MPWRs valuation compared to sectorStock Surge & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
How Analyst Revisions Are Rewriting The Story For Plus Therapeutics (PSTV) - Yahoo Finance
Merger Talk: What is the dividend yield of Plus Therapeutics IncPortfolio Gains Summary & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Plus Therapeutics (PSTV) Gets a Buy from Lake Street - The Globe and Mail
Market Rankings: Is Plus Therapeutics Inc stock undervalued right nowBond Market & Daily Entry Point Alerts - baoquankhu1.vn
Exit Recap: What is Atlas Lithium Corporations revenue forecastJuly 2025 Movers & AI Enhanced Execution Alerts - baoquankhu1.vn
Plus Therapeutics shares climb after subsidiary secures nationwide Humana coverage - MSN
Plus Therapeutics, Inc. (PSTV) Discusses Business Update, REYOBIQ Clinical Program Progress, and Recent Financial OfferingSlideshow (NASDAQ:PSTV) 2026-01-30 - Seeking Alpha
Is Plus Therapeutics Inc. a top pick in the sectorQuarterly Risk Review & Free Technical Pattern Based Buy Signals - mfd.ru
Bond Watch: What is the cash position of LifeMD IncJuly 2025 Momentum & Weekly High Momentum Picks - baoquankhu1.vn
Published on: 2026-01-27 09:16:26 - baoquankhu1.vn
Institution Moves: Is Plus Therapeutics Inc on track to beat earningsTrade Signal Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Price Action: Is Euroholdings Ltd. stock showing strong momentumJuly 2025 Recap & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
H.C. Wainwright lowers Plus Therapeutics stock price target on equity offering - Investing.com India
Maxim Group Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Cuts Target Price to $1.5 - 富途牛牛
Plus Therapeutics secures $5.7M to support leptomeningeal metastases program - MSN
H.C. Wainwright Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Cuts Target Price to $1 - 富途牛牛
Plus Therapeutics (PSTV) Sees Price Target Cut by HC Wainwright | PSTV Stock News - GuruFocus
Plus Therapeutics outlines 2026 goals for cancer treatments and diagnostics By Investing.com - Investing.com South Africa
Aug Mood: Is ABCL forming higher highs and higher lowsJuly 2025 Analyst Calls & Weekly Top Gainers Trade List - baoquankhu1.vn
Market Review: What dividend growth rate does Plus Therapeutics Inc offerWeekly Gains Summary & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Plus Therapeutics, Inc. Provides Business Update on REYOBIQ Clinical Program and U.S. CNSide Commercialization - marketscreener.com
PSTV: $15M raise funds clinical and commercial growth; CNSIDE targets break-even by 2027 - TradingView — Track All Markets
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET - Sahm
Plus Therapeutics Sets 2026 Milestones For REYOBIQ Clinical Program And CNSide Commercial Rollout - Nasdaq
Plus Therapeutics outlines 2026 goals for cancer treatments and diagnostics - Investing.com
PSTV Analyst Rating Update: Price Target Lowered to $4.00 | PSTV Stock News - GuruFocus
Plus Therapeutics Sharpens Focus on CNS Cancer Strategy - TipRanks
Plus Therapeutics Inc (PSTV) 財務データ
収益
当期純利益
現金流量
EPS
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):